When Sarvjeet and Tajinder Virk founded Finvasia in 2009, they weren’t just building a company—they were challenging the way industries operate. What started as a fintech venture has grown into a global powerhouse spanning financial services, healthcare, biomedical engineering, and investment banking. With over 5 million clients in 190+ countries, Finvasia’s disruptive products are reshaping markets, making them more accessible, transparent, and technology-driven.
But Finvasia is not just another company—it’s an ecosystem of innovation. Whether it’s revolutionizing stock trading, copy trading, AI-driven banking, medicine derived from food, or wearable biosensors, the company is proving that real-world problems need interdisciplinary solutions.
Shoonya: The Zero-Commission Trading Disruptor
If there’s one product that put Finvasia on the map, it’s Shoonya—India’s first truly zero-commission trading platform. Launched to democratize investing, Shoonya disrupted the brokerage industry by eliminating trading fees across equities, commodities, derivatives, and currencies.
For traders, this meant more than just savings—it meant unrestricted access to markets without hidden costs. As a result, Shoonya has seen exponential adoption, attracting millions of retail investors and forcing traditional brokers to rethink their pricing models.
ZuluTrade: Social Trading on a $2 Trillion Scale
On the global stage, Finvasia expanded into social trading with the acquisition of ZuluTrade in 2021. Founded in 2007, ZuluTrade has facilitated over $2 trillion in trades and serves users in 150+ countries.
ZuluTrade is not just a copy-trading platform—it’s an ecosystem where traders, investors, and brokers connect. Under Finvasia’s leadership, the platform is evolving beyond copy trading, integrating AI, risk analytics, and user-driven enhancements to make investing more collaborative and data-driven.
Jumpp: AI-Powered Neo-Banking for the Future
Traditional banking is complex, fragmented, and outdated—Finvasia’s answer to this? Jumpp.
Jumpp is an AI-driven neo-banking super app that combines banking, savings, payments, investing, and lending into a single, intelligent platform. Unlike traditional apps, Jumpp isn’t just about transactions—it’s about financial empowerment.
Using multilingual AI, it provides spending insights, budgeting recommendations, and personalized financial strategies. Built in collaboration with YES Bank, Jumpp is not just another fintech app—it’s a step toward fully automated, user-centric banking.
Ethniq: Transforming Medicine Through Food Science
What if food could be medicine—literally? That’s the philosophy behind Ethniq, a pioneering venture that develops pharmaceuticals derived from natural food sources.
Unlike traditional drug development, Ethniq creates plant-based, scientifically validated medicines. With 10 products already approved by FSSAI and AYUSH India, Ethniq is leading a new frontier in holistic healthcare.
It has also received a patent for one of its innovative medicines and is awaiting approval for several others. This approach is not just about treating diseases but preventing them—a radical shift in how medicine is developed and consumed.
ActTrader: A Powerhouse in Trading Technology
With financial markets evolving rapidly, professional traders demand high-performance trading platforms. Finvasia’s ActTrader is exactly that—a battle-tested, institutional-grade trading technology that has powered global financial institutions for over two decades.
Designed for high-frequency traders and institutional investors, ActTrader ensures seamless execution, algorithmic trading, and multi-asset support, making it a critical pillar in Finvasia’s financial ecosystem.
Bodyloop: The Future of Biomedical Engineering
Wearable health trackers are common—but what if your body itself could monitor its health? Bodyloop is bringing that vision to life.
Finvasia is developing ‘in-body’ microsensors that will allow real-time, continuous monitoring of vital health parameters. This cutting-edge biomedical engineering project aims to revolutionize early disease detection and patient care, taking personal healthcare beyond wearables and into seamless, real-time bio-monitoring.
Gini Health: A DNA-Based Approach to Diabetes Reversal
Prevention is better than cure, but what if chronic diseases like diabetes could be reversed?
Gini Health is an innovative DNA-based and diabetes reversal healthcare facility that provides end-to-end treatment, from ICU to OPD. By integrating genomics, AI-driven diagnostics, and precision medicine, Gini Health creates personalized treatment plans aimed at reversing diabetes, rather than just managing it.
This science-driven, patient-centric approach makes Gini Health a game-changer in tackling one of the world’s biggest health crises.
A Global Financial and Investment Banking Powerhouse
Beyond fintech and healthcare, Finvasia is deeply entrenched in global finance, with brokerage and investment banking operations spanning Mauritius, UAE, South Africa, and the EU.
Its brokerage platforms serve retail and institutional clients, providing low-cost, high-efficiency trading solutions. Meanwhile, its investment banking arm focuses on capital markets, structured finance, and strategic advisory services, solidifying Finvasia’s reputation as a serious player in global finance.
What’s Next for Finvasia?
Few companies can claim expertise across financial services, AI, medicine, and biomedical engineering—but Finvasia thrives on breaking boundaries.
With ongoing patents, rapid global expansion, and cutting-edge technology in multiple industries, Finvasia is not just shaping the future—it’s creating it. Whether it’s making trading free, revolutionizing banking, redefining medicine, or pioneering bio-sensing technology, the company is proving that the most disruptive innovations happen when industries intersect.
As Finvasia continues to grow, one thing is clear: this isn’t just a company to watch—it’s one that’s changing the way we think about finance, health, and technology altogether.
When Sarvjeet and Tajinder Virk founded Finvasia in 2009, they weren’t just building a company—they were challenging the way industries operate. What started as a fintech venture has grown into a global powerhouse spanning financial services, healthcare, biomedical engineering, and investment banking. With over 5 million clients in 190+ countries, Finvasia’s disruptive products are reshaping markets, making them more accessible, transparent, and technology-driven.
But Finvasia is not just another company—it’s an ecosystem of innovation. Whether it’s revolutionizing stock trading, copy trading, AI-driven banking, medicine derived from food, or wearable biosensors, the company is proving that real-world problems need interdisciplinary solutions.
Shoonya: The Zero-Commission Trading Disruptor
If there’s one product that put Finvasia on the map, it’s Shoonya—India’s first truly zero-commission trading platform. Launched to democratize investing, Shoonya disrupted the brokerage industry by eliminating trading fees across equities, commodities, derivatives, and currencies.
For traders, this meant more than just savings—it meant unrestricted access to markets without hidden costs. As a result, Shoonya has seen exponential adoption, attracting millions of retail investors and forcing traditional brokers to rethink their pricing models.
ZuluTrade: Social Trading on a $2 Trillion Scale
On the global stage, Finvasia expanded into social trading with the acquisition of ZuluTrade in 2021. Founded in 2007, ZuluTrade has facilitated over $2 trillion in trades and serves users in 150+ countries.
ZuluTrade is not just a copy-trading platform—it’s an ecosystem where traders, investors, and brokers connect. Under Finvasia’s leadership, the platform is evolving beyond copy trading, integrating AI, risk analytics, and user-driven enhancements to make investing more collaborative and data-driven.
Jumpp: AI-Powered Neo-Banking for the Future
Traditional banking is complex, fragmented, and outdated—Finvasia’s answer to this? Jumpp.
Jumpp is an AI-driven neo-banking super app that combines banking, savings, payments, investing, and lending into a single, intelligent platform. Unlike traditional apps, Jumpp isn’t just about transactions—it’s about financial empowerment.
Using multilingual AI, it provides spending insights, budgeting recommendations, and personalized financial strategies. Built in collaboration with YES Bank, Jumpp is not just another fintech app—it’s a step toward fully automated, user-centric banking.
Ethniq: Transforming Medicine Through Food Science
What if food could be medicine—literally? That’s the philosophy behind Ethniq, a pioneering venture that develops pharmaceuticals derived from natural food sources.
Unlike traditional drug development, Ethniq creates plant-based, scientifically validated medicines. With 10 products already approved by FSSAI and AYUSH India, Ethniq is leading a new frontier in holistic healthcare.
It has also received a patent for one of its innovative medicines and is awaiting approval for several others. This approach is not just about treating diseases but preventing them—a radical shift in how medicine is developed and consumed.
ActTrader: A Powerhouse in Trading Technology
With financial markets evolving rapidly, professional traders demand high-performance trading platforms. Finvasia’s ActTrader is exactly that—a battle-tested, institutional-grade trading technology that has powered global financial institutions for over two decades.
Designed for high-frequency traders and institutional investors, ActTrader ensures seamless execution, algorithmic trading, and multi-asset support, making it a critical pillar in Finvasia’s financial ecosystem.
Bodyloop: The Future of Biomedical Engineering
Wearable health trackers are common—but what if your body itself could monitor its health? Bodyloop is bringing that vision to life.
Finvasia is developing ‘in-body’ microsensors that will allow real-time, continuous monitoring of vital health parameters. This cutting-edge biomedical engineering project aims to revolutionize early disease detection and patient care, taking personal healthcare beyond wearables and into seamless, real-time bio-monitoring.
Gini Health: A DNA-Based Approach to Diabetes Reversal
Prevention is better than cure, but what if chronic diseases like diabetes could be reversed?
Gini Health is an innovative DNA-based and diabetes reversal healthcare facility that provides end-to-end treatment, from ICU to OPD. By integrating genomics, AI-driven diagnostics, and precision medicine, Gini Health creates personalized treatment plans aimed at reversing diabetes, rather than just managing it.
This science-driven, patient-centric approach makes Gini Health a game-changer in tackling one of the world’s biggest health crises.
A Global Financial and Investment Banking Powerhouse
Beyond fintech and healthcare, Finvasia is deeply entrenched in global finance, with brokerage and investment banking operations spanning Mauritius, UAE, South Africa, and the EU.
Its brokerage platforms serve retail and institutional clients, providing low-cost, high-efficiency trading solutions. Meanwhile, its investment banking arm focuses on capital markets, structured finance, and strategic advisory services, solidifying Finvasia’s reputation as a serious player in global finance.
What’s Next for Finvasia?
Few companies can claim expertise across financial services, AI, medicine, and biomedical engineering—but Finvasia thrives on breaking boundaries.
With ongoing patents, rapid global expansion, and cutting-edge technology in multiple industries, Finvasia is not just shaping the future—it’s creating it. Whether it’s making trading free, revolutionizing banking, redefining medicine, or pioneering bio-sensing technology, the company is proving that the most disruptive innovations happen when industries intersect.
As Finvasia continues to grow, one thing is clear: this isn’t just a company to watch—it’s one that’s changing the way we think about finance, health, and technology altogether.
